8-K: SeaStar Medical to Restate Financials and Provide Business Update on April 17th

SeaStar Medical will restate its financial statements for 2022 and interim 2023 periods due to accounting treatment of certain financial instruments, and will host a business update call on April 17th.

Summary

• SeaStar Medical is restating its financial statements for the fiscal year ended December 31, 2022, and the interim periods ended March 31, 2023, June 30, 2023, and September 30, 2023.
• The restatement is due to the accounting treatment and classification of certain outstanding warrants and a prepaid forward purchase arrangement that was terminated in June 2023.
• The company expects to file Form 12b-25 with the SEC, which provides a 15-day grace period for filing the Annual Report on Form 10-K.
• The restatement is not expected to have a material impact on the company's business operations or cash position, as it relates to non-cash accounting items.
• SeaStar Medical will host a business update conference call on April 17, 2024, at 4:00 p.m. Eastern time to discuss the restatement and provide an operational update.
• The company's pivotal adult acute kidney injury (AKI) study has enrolled 23 subjects, with two additional subjects enrolled since the last update two weeks ago.
• The first critically ill child with AKI and sepsis is expected to be treated with the Quelimmune pediatric device in the second quarter of 2024.
• The FDA granted a Humanitarian Device Exemption (HDE) Approval Order to the Quelimmune pediatric device in February 2024.
• SeaStar Medical estimates the eligible population for its Quelimmune pediatric device to be approximately 4,000 children annually with AKI.
• The NEUTRALIZE-AKI pivotal trial is expected to enroll up to 200 adults to evaluate the Selective Cytopheretic Device (SCD).

Sentiment

Score: 4

Explanation: The need for a financial restatement and a delay in filing the annual report are negative signals, although the company is making progress in clinical trials and commercialization. The sentiment is cautiously optimistic due to the potential of the technology but tempered by the financial issues.

Positives

• The restatement is not expected to have a material impact on the company's cash position or operations.
• The company is making progress with its pivotal adult AKI study, with 23 subjects enrolled.
• The commercial launch of the Quelimmune pediatric device is progressing, with the first patient treatment expected in Q2 2024.
• The FDA granted HDE approval for the Quelimmune pediatric device in February 2024.
• The company is actively engaging with key opinion leaders and sharing insights at conferences.

Negatives

• The company needs to restate its financial statements for 2022 and interim 2023 periods.
• The restatement is due to complex financial instruments related to the company's SPAC route to becoming public.
• The company will need to file Form 12b-25 with the SEC, indicating a delay in filing the Annual Report on Form 10-K.

Risks

• The company may face challenges in obtaining regulatory approval for its SCD product candidates.
• There is a risk that the company may not be able to raise sufficient capital to fund its operations and clinical trials.
• The company may experience delays in developing and commercializing its products.
• There is a risk that the company may not achieve or sustain profitability.
• The company may face risks related to third-party suppliers and manufacturers.
• The company may face product liability or regulatory lawsuits.
• The company may be unable to secure or protect its intellectual property.

Future Outlook

The company expects to provide a more detailed update on its progress and outlook during the business update conference call on April 17, 2024. They also anticipate the first pediatric patient treatment with Quelimmune in the second quarter of 2024.

Management Comments

• The restatement is not expected to have a material impact on our business operations or our cash position, but rather is related to the reporting of non-cash accounting items, said Eric Schlorff, Chief Executive Officer of SeaStar Medical.
• We pursued a Special Purpose Acquisition Company (SPAC) as our route to become a public company in late 2022 due to the challenging market conditions at that time.
• Many SPACs, including ours, relied on a host of complex financial instruments.
• Unfortunately, we determined that certain complex financial instruments required accounting treatment that differed from our previous judgment, which led to the need for a restatement.
• Importantly, we continue to make progress with our pivotal adult acute kidney injury (AKI) study with 23 subjects enrolled, including two additional subjects since our last update two weeks ago.
• With our commercial launch of the Quelimmune pediatric therapeutic device, the first critically ill child with AKI and sepsis or septic condition is expected to be treated at a well-recognized childrens hospital in the second quarter of 2024.
• We are excited to provide access to our symposium, New Therapies in Pediatric Acute Kidney Injury, held at the AKI-CRRT 2024 conference earlier this month, with key opinion leaders from our Scientific Advisory Board sharing valuable insights into AKI and sepsis, as well as their experiences with Quelimmune.

Industry Context

The announcement highlights the challenges faced by companies that went public via SPACs, particularly regarding the accounting treatment of complex financial instruments. The focus on AKI and sepsis aligns with the growing need for innovative therapies in critical care, and the company's progress in both adult and pediatric trials positions them as a potential player in this space.

Comparison to Industry Standards

• The need for a financial restatement due to complex financial instruments is not uncommon among companies that went public via SPACs, indicating a broader issue in the industry.
• The enrollment of 23 subjects in the adult AKI trial is a positive step, but the total target of 200 is still a significant undertaking, and the pace of enrollment will be important to monitor.
• The expected treatment of the first pediatric patient in Q2 2024 is a key milestone, and the company's estimate of 4,000 eligible patients annually suggests a significant market opportunity.
• Companies like Baxter and Fresenius Medical Care are major players in the kidney replacement therapy market, and SeaStar Medical's SCD technology represents a novel approach that could differentiate them from these established players.
• The use of a Humanitarian Device Exemption (HDE) for the pediatric device is a common regulatory pathway for devices targeting rare conditions, and the company's success in obtaining this approval is a positive sign.

Stakeholder Impact

• Shareholders may be concerned about the financial restatement and the delay in filing the annual report.
• Employees may be affected by the uncertainty surrounding the financial restatement.
• Customers and patients may be interested in the progress of the clinical trials and the commercialization of the company's products.
• Suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• The company will host a business update conference call on April 17, 2024.
• The company will file Form 12b-25 with the SEC.
• The company will continue to enroll subjects in the pivotal adult AKI study.
• The company expects to treat the first pediatric patient with Quelimmune in the second quarter of 2024.

Key Dates

Keywords

SeaStar Medical, financial restatement, acute kidney injury, AKI, Quelimmune, Selective Cytopheretic Device, SCD, hyperinflammation, pediatric, clinical trial, FDA, HDE, warrants, SPAC